Clinical Scorecard: Timing of Antimicrobial Therapy in Infective Endocarditis: Is a Delay Justified?
At a Glance
Category
Detail
Condition
Infective Endocarditis (IE)
Key Mechanisms
Bacteremia with suspected IE; empirical antimicrobial treatment timing after blood culture collection
Target Population
Adult patients with suspected IE who are hemodynamically stable without sepsis or ICU admission
Care Setting
Tertiary care hospitals with infectious diseases consultation and Endocarditis Team adjudication
Key Highlights
Immediate empirical antimicrobial treatment after blood culture collection is guideline-recommended but its benefit in stable patients is uncertain.
In a multicenter cohort of 1230 episodes, deferring antimicrobial therapy until preliminary blood culture results did not increase 30-day mortality or adverse outcomes.
Deferring treatment may reduce unnecessary broad-spectrum antimicrobial use and antimicrobial resistance in patients without confirmed IE.
Guideline-Based Recommendations
Diagnosis
Obtain 3 sets of blood cultures before initiating antimicrobial therapy in suspected IE.
Use echocardiography and multidisciplinary Endocarditis Team adjudication for diagnosis confirmation.
Management
European and American guidelines recommend prompt empirical antimicrobial treatment after blood cultures in suspected IE.
British Society for Antimicrobial Chemotherapy suggests withholding antimicrobials in clinically stable patients until blood culture results are available.
Monitoring & Follow-up
Perform follow-up blood cultures until bloodstream sterilization is confirmed.
Monitor for 30-day mortality, embolic events, and new bone/joint infections in confirmed IE cases.
Risks
Immediate empirical antimicrobial therapy may lead to overtreatment in patients without IE.
Broad-spectrum empirical regimens increase risk of antimicrobial resistance.
Delaying therapy in unstable patients (sepsis, ICU admission) is not supported.
Patient & Prescribing Data
Adult patients with bacteremia and suspected IE excluding those with sepsis, ICU admission, neutropenia, or other infection foci
Deferring antimicrobial therapy until preliminary blood culture results did not worsen 30-day mortality or composite adverse outcomes in stable patients.
Clinical Best Practices
Obtain multiple blood cultures prior to antimicrobial initiation in suspected IE.
Involve infectious diseases specialists and Endocarditis Teams for diagnosis and management decisions.
Consider deferring antimicrobial therapy in clinically stable patients until preliminary blood culture results to avoid unnecessary broad-spectrum antibiotic exposure.
Initiate immediate antimicrobial therapy in patients presenting with sepsis, septic shock, or hemodynamic instability.
by Elisavet Stavropoulou, Bruno Ledergerber, Nicolas Fourré, Virgile Zimmermann, Jana Epprecht, Nicoleta Ianculescu, Pierre Monney, Georgios Tzimas, Michelle Frank, Laurence Senn, Lars Niclauss, Matthias Kirsch, Mathias Van Hemelrijck, Omer Dzemali, Benoit Guery, Barbara Hasse, Matthaios Papadimitriou-Olivgeris
Phase 3 ENHANCE-1 results showed higher composite clinical cure and microbiologic response rates with cefepime-zidebactam vs meropenem in hospitalized adults with complicated urinary tract infection or acute pyelonephritis.
